IL-17 inhibitors increase risk of IBD. TriNetX database study of PsO & AS pts starting IL-17i vs apremilast. 13,216 matched pts per group, 142 developed IBD w/ IL-17i vs. 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). https://t.co/sSPqKsfbZ4 https://t.co/YCqDUzX9xq
Links:
Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psori…
https://buff.ly/TJ8wWJ1
Apr-25-2025
